Back
Akebia Therapeutics Vs. SELLAS Life Sciences Group Industry Stock Comparison
Sell
42
AKBA
Akebia Therapeutics
Last Price:
1.16
Seasonality Move:
-7.41%
Sell
48
SLS
SELLAS Life Sciences Group
Last Price:
1.47
Seasonality Move:
-14.78%
Sell
42
Akebia Therapeutics (AKBA)
is a Sell
Is Akebia Therapeutics a Buy, Sell or Hold?
- The current Akebia Therapeutics [AKBA] share price is $1.15. The Score for AKBA is 42, which is 16% below its historic median score of 50, and infers higher risk than normal.
- AKBA is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
Sell
48
SELLAS Life Sciences Group (SLS)
is a Sell
Is SELLAS Life Sciences Group a Buy, Sell or Hold?
- The current SELLAS Life Sciences Group [SLS] share price is $1.46. The Score for SLS is 48, which is 4% below its historic median score of 50, and infers higher risk than normal.
- SLS is currently trading in the 40-50% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a lower than normal reading, suggesting risk levels may be somewhat higher than normal and additional caution is warranted.
AKBA Stock Price Chart
What is Akebia Therapeutics's stock price today?
-
The Akebia Therapeutics share price today is $1.15
Based on the share price being below its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bearish and AKBA is experiencing slight selling pressure.
SLS Stock Price Chart
What is SELLAS Life Sciences Group's stock price today?
-
The SELLAS Life Sciences Group share price today is $1.46
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and SLS is experiencing slight selling pressure.
AKBA Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.08 | Sell |
| Relative Strength Index (14 RSI): | 36.32 | Sell |
| Chaikin Money Flow: | 0 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (1.23 - 1.41) | Sell |
| Bollinger Bands (100): | (1.29 - 1.73) | Sell |
SLS Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 0.03 | Buy |
| Relative Strength Index (14 RSI): | 58.82 | Buy |
| Chaikin Money Flow: | -561726 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (1.29 - 1.51) | Buy |
| Bollinger Bands (100): | (0.7 - 1.38) | Buy |
AKBA Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.24 | Sell |
| 20-day SMA: | 1.3 | Sell |
| 50-day SMA: | 1.5 | Sell |
| 200-day SMA: | 1.31 | Sell |
| 8-day EMA: | 1.22 | Sell |
| 20-day EMA: | 1.31 | Sell |
| 50-day EMA: | 1.41 | Sell |
| 200-day EMA: | 1.32 | Sell |
SLS Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 1.38 | Buy |
| 20-day SMA: | 1.39 | Buy |
| 50-day SMA: | 1.31 | Buy |
| 200-day SMA: | 1.15 | Buy |
| 8-day EMA: | 1.41 | Buy |
| 20-day EMA: | 1.38 | Buy |
| 50-day EMA: | 1.28 | Buy |
| 200-day EMA: | 1.28 | Buy |
Akebia Therapeutics Earnings Growth & AKBA Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.00 per share, an increase next quarter of $0.10 per share, an increase this year of $0.05 per share, and an increase next year of $0.05 per share.
SELLAS Life Sciences Group Earnings Growth & SLS Earnings Dates
- Analysts estimate an earnings increase this quarter of $0.19 per share, a decrease next quarter of $0.00 per share, an increase this year of $0.40 per share, and an increase next year of $0.01 per share.
Akebia Therapeutics Technical Analysis
| May 6 | May 7 | May 8 | May 9 | May 10 | May 13 | May 14 | May 15 | May 16 | May 17 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 06 | 07 | 08 | 09 | 10 | 13 | 14 | 15 | 16 | 17 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
SELLAS Life Sciences Group Technical Analysis
| May 6 | May 7 | May 8 | May 9 | May 10 | May 13 | May 14 | May 15 | May 16 | May 17 | |
|---|---|---|---|---|---|---|---|---|---|---|
| May | ||||||||||
| 06 | 07 | 08 | 09 | 10 | 13 | 14 | 15 | 16 | 17 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||